Acinar ductal carcinoma of prostate – pro
Ductal carcinoma of the prostate is a rare histologic subtype of prostate carcinoma. It represents 0.4% to 0.8% of all prostate cancers and is associated with a poor prognosis. Given the paucity of cases reported in the literature on ductal prostate carcinoma, little is known about how this cancer responds to cytotoxic chemotherapy1. It is a rare variant; the largest review2 reported on 31 patients. Based on this limited data, it seems that this is a cancer with a behavior similar to that of high Gleason grade acinar carcinoma. Good local control can be achieved by either radiation or surgery. Postoperative radiotherapy seems to work as an adjuvant or salvage treatment, and most tumors appear to respond to androgen deprivation. There are no FDA approved agents for this diagnosis and chemotehrapy and anti-hormonal combinations have not been sufficiently studied.
Epstein J.I., Prostatic Ductal Adenocarcinoma: A Mini Review. Med Princ Pract 2010;19:8285
Idem et al, Prostatic Duct Adenocarcinoma: Clinical Characteristics, Treatment Options, and Outcomes a Rare Cancer Network Study. Onkologie 2010;33:169173